First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma
In vitro statins overcome cell adhesion‐mediated drug resistance at non‐toxic concentrations that are achievable in humans by standard dose simvastatin. A pilot phase‐II trial was initiated to determine feasibility and antimyeloma efficacy. In six myeloma patients refractory to two cycles of bortezo...
Saved in:
Published in | European journal of haematology Vol. 79; no. 3; pp. 240 - 243 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.09.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In vitro statins overcome cell adhesion‐mediated drug resistance at non‐toxic concentrations that are achievable in humans by standard dose simvastatin. A pilot phase‐II trial was initiated to determine feasibility and antimyeloma efficacy. In six myeloma patients refractory to two cycles of bortezomib or bendamustine simvastatin was concomitantly administered during further two cycles. The therapy was well tolerated without grade 3/4 toxicity. Intrapatient (cycles I/II vs. III/IV) and interpatient comparison (vs. ten patients without simvastatin) showed reduction of drug resistance by inhibition of HMG‐CoA‐reductase. In summary, this is the first phase II experience to study antimyeloma activity of statins in humans. |
---|---|
Bibliography: | ark:/67375/WNG-NT0WP870-0 ArticleID:EJH902 istex:F097501C8B92B8150B4A3348BB650D4B313ECCDE |
ISSN: | 0902-4441 1600-0609 |
DOI: | 10.1111/j.1600-0609.2007.00902.x |